Z

Zyversa Therapeutics Inc
NASDAQ:ZVSA

Watchlist Manager
Zyversa Therapeutics Inc
NASDAQ:ZVSA
Watchlist
Price: 0.1343 USD -0.15% Market Closed
Market Cap: 1.1m USD

Zyversa Therapeutics Inc
Operating Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Zyversa Therapeutics Inc
Operating Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Operating Income CAGR 3Y CAGR 5Y CAGR 10Y
Z
Zyversa Therapeutics Inc
NASDAQ:ZVSA
Operating Income
-$9.1m
CAGR 3-Years
-6%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Operating Income
$19.7B
CAGR 3-Years
0%
CAGR 5-Years
9%
CAGR 10-Years
13%
Gilead Sciences Inc
NASDAQ:GILD
Operating Income
$11.3B
CAGR 3-Years
6%
CAGR 5-Years
7%
CAGR 10-Years
-6%
Amgen Inc
NASDAQ:AMGN
Operating Income
$12.1B
CAGR 3-Years
6%
CAGR 5-Years
6%
CAGR 10-Years
4%
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Operating Income
$4.5B
CAGR 3-Years
2%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Operating Income
$3.9B
CAGR 3-Years
-17%
CAGR 5-Years
4%
CAGR 10-Years
12%
No Stocks Found

Zyversa Therapeutics Inc
Glance View

Market Cap
1.1m USD
Industry
Biotechnology

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. The company is headquartered in Weston, Florida. The company went IPO on 2021-12-21. The firm is focused on leveraging advanced technologies to develop drugs for patients with renal or inflammatory diseases. The Company’s development pipeline includes renal drug candidate, namely VAR 200, (2-hydroxypropyl-beta-cyclodextrin or 2HPβCD), a cholesterol efflux mediator for treatment of rare kidney disease, focal segmental glomerulosclerosis. Its VAR 200 has potential to treat other glomerular diseases, including alport syndrome and diabetic kidney disease. The firm's development pipeline also includes anti-inflammatory drug candidate, namely IC 100, an inflammasome ASC inhibitor being developed to treat a multitude of inflammatory diseases. Its phase 2a renal product candidate, VAR 200, which mediates removal of excess intracellular lipids that contribute to kidney damage leading to end-stage renal disease.

ZVSA Intrinsic Value
0.189 USD
Undervaluation 29%
Intrinsic Value
Price
Z

See Also

What is Zyversa Therapeutics Inc's Operating Income?
Operating Income
-9.1m USD

Based on the financial report for Dec 31, 2024, Zyversa Therapeutics Inc's Operating Income amounts to -9.1m USD.

What is Zyversa Therapeutics Inc's Operating Income growth rate?
Operating Income CAGR 3Y
-6%

Over the last year, the Operating Income growth was 37%. The average annual Operating Income growth rates for Zyversa Therapeutics Inc have been -6% over the past three years .

Back to Top